Question for written answer E-003965/2015
to the Commission
Rule 130
Gabriel Mato (PPE) and Carlos Iturgaiz (PPE)

Subject: Operation of the common system of identification of medicinal products in the EU

A few years ago the European Union committed itself to set up a system for unique identification of medicinal products. The main objectives of this system were to improve patient safety, make it easier to detect false products, improve the control of distribution and stock management of the products covered, and identify products used upon reimbursement of treatment costs.

The system laid down requirements for manufacturers and health centres and provided for the creation of a centralised database of medicinal products.

What is the Commission's assessment of how this system has been operating?

What are the main obstacles that the Commission has come across in this process?

How have citizens benefited from the improvement of the system?